



BIONXT SECURES CONTRACT TO DEVELOP AND MANUFACTURE ODF PRODUCT FOR INTERNATIONAL PHARMACEUTICAL COMPANY

VANCOUVER, BC – April 24, 2023 - BioNxt Solutions Inc. (“**BioNxt**” or the “**Company**”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to announce that it has signed and received payment for a development and manufacturing contract (the “Contract”) with an international pharmaceutical company (the “Client”). The Contract is focused on the development of an oral dissolvable (“ODF”) pharmaceutical product based on BioNxt’s ODF platform technology. The Contract includes provisions for product development, contract manufacturing for technical samples and product stability testing.

“On April 17, 2023, BioNxt announced the purchase of state-of-the-art coating and cutting equipment to build out commercial manufacturing capacity at its German facility,” noted Hugh Rogers, CEO of BioNxt. “Commercial manufacturing capability is designed to complement the Company’s in-house drug development programs and provide additional high-value services for third party clients as they prepare for commercialization. Today’s Contract is the second such agreement in the past 12 months. In general, we see this type of contract work as a significant business opportunity with high growth potential.”

BioNxt’s wholly owned subsidiary, Vektor Pharma TF GmbH, is a German drug development and manufacturing company with narcotics licences located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of innovative, non-invasive drug delivery systems, particularly transdermal patches and sub-lingual strips for the delivery of active pharmaceutical ingredients for the treatment of pain and neurological conditions. According to Precedence Research, the global pharmaceutical drug delivery market size was valued at USD 1,525 billion in 2022 and expected to surpass approximately USD 2,047 billion by 2030.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.



BioNxt Solutions Inc.

Hugh Rogers
CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422

Cautionary Statement Regarding “Forward-Looking” Information

Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as “expects”, “intends”, “is expected”, “potential”, “suggests” or variations of such words or phrases, or statements that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company’s control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.